Clinical Trials Directory
We are doing this study to collect data, liquid biopsies (blood and urine), and cancer specimens from women with primary epithelial ovarian, peritoneal, or tubal cancer. We are using this information and these samples to create a biobank that might identify future therapeutic targets and help develop new therapies for these types of cancer.
We are doing this study to test if an experimental medical device called the Bioenthesis® implant (the study device) is a safe and effective option for people who are having surgery to repair a torn rotator cuff. The study device is a bubble gum strip-sized, sponge-like scaffold that is made of real human tissue. The implant has two layers: a soft tissue layer to merge with your tendon, and a hard tissue layer to allow a patient's own stem cells to populate the implant from the bone marrow.
We are doing this study to find the most effective, safe dose of an experimental drug called BHV-1530 (the study drug) for adults who have advanced or metastatic solid tumors.
We are doing this study to find the most effective, safe dose of an experimental drug called BNT326. We want to know how well it works when it is given on its own and in combination with an immunotherapy drug.
Collection of samples will allow for increased and more focused research on skin conditions and perhaps eventually lead to the development of improved treatment outcomes.
We are doing this study to learn more about how repeated head impacts and concussions from playing sports can impact the health of Black men after middle age (age 50 and above). We want to find out how these injuries might affect things like lifestyle, mood, brain structure, socioeconomic status, and blood markers of brain disease. We hope this study can help reduce disparities in outcomes and improve the detection and diagnosis of brain health.
The study starts with a screening period that lasts about 4 weeks and includes 1 or 2 visits. Treatment can last up to about 2 years with up to 43 visits. After treatment ends, follow-up continues for about 1 year with up to 6 visits. The study medicine is given through an IV every 3 weeks, and each visit lasts about 60 minutes. In Part 1 of the study, researchers test the medicine BMS 986525 by itself or with another medicine called nivolumab to find a safe dose. In Part 2, the chosen dose or doses are tested in larger groups. If more than one dose is available, a computer may randomly choose which dose a person receives.